Core Insights - Salarius Pharmaceuticals is advancing its Phase 1/2 clinical study of seclidemstat for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with updates expected later this year [1][2] - The company is progressing with its planned merger with Decoy Therapeutics, which is anticipated to create value through Decoy's innovative peptide conjugate therapeutics [2][3] Company Developments - Salarius' seclidemstat is a first-in-class, orally bioavailable LSD1 inhibitor being evaluated at MD Anderson Cancer Center [1][9] - The merger with Decoy Therapeutics is set to combine Salarius' drug candidates with Decoy's IMPACT™ platform, which focuses on developing therapeutics for respiratory viruses and cancer [3][10] - The combined company will be led by Decoy's executive team, including CEO Frederick "Rick" Pierce and CSO Barbara Hibner [4] Research Insights - Two recent animal studies highlight the importance of inhibiting LSD1 expression, supporting the potential of SP-2577 in cancer treatment [2][5] - The studies published in peer-reviewed journals provide insights into the role of KDM1A in regulating neural stem cells and oral squamous cell carcinoma progression [5] Future Plans - Decoy plans to advance its lead asset, a pan-coronavirus antiviral, towards an Investigational New Drug (IND) application with the FDA within the next 12 months [6] - The ongoing clinical trial at MDACC may yield data on MDS and CMML patients who have previously failed or relapsed after hypomethylating agent therapy [7]
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies